News|Articles|November 17, 2026

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • TARBELA-AD randomizes adults 50–90 years with biomarker-confirmed amyloid pathology and CDR-Global 0.5–1.0 to RG6434 high dose, low dose, or placebo for 72 weeks.
  • Change from baseline in CDR-SB at week 72 is primary; ADAS-Cog-13, ADCS-ADL, suicidality, adverse events, and plasma PK comprise key secondary outcomes.
SHOW MORE

A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Recruitment has begun for TARBELA-AD, a placebo-controlled trial testing whether calming the brain's NLRP3 inflammasome can slow Alzheimer disease (AD) alongside existing amyloid-targeted therapies. The design was presented as a poster at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, building on several years of laboratory and human biomarker work linking NLRP3 activation to tau pathology and faster cognitive decline.1,2

TARBELA-AD (NCT07781657) is a global, multicenter, randomized, double-blind, placebo-controlled phase 2 trial evaluating RG6434, also known by its earlier compound code RO7568282, in adults with early symptomatic AD. Participants are randomized 1:1:1 to RG6434 high dose, RG6434 low dose, or placebo for a 72-week double-blind treatment period, preceded by up to 56 days of screening and followed by a 28-day safety follow-up. The trial plans to enroll approximately 450 participants across 17 countries, with recruitment estimated to start in October 2026 and primary completion estimated for November 2029.1,2

“Amyloid clearance remains a vital foundation, but halting a disease as complex as Alzheimer's demands multifaceted and complementary strategies,” said Levi Garraway, MD, PhD, Roche's chief medical officer and head of global product development, adding that the company will test additional therapeutic hypotheses aimed at stopping or preventing disease progression.2

The primary endpoint is change from baseline to week 72 in the Clinical Dementia Rating-Sum of Boxes, a composite measure of cognitive and functional decline. Secondary endpoints include change on the ADAS-Cog-13 cognitive scale and the ADCS-ADL activities-of-daily-living inventory, alongside adverse event incidence, change on the Columbia-Suicide Severity Rating Scale, and RG6434's plasma pharmacokinetic profile. Exploratory objectives include changes in NLRP3- and Alzheimer-related plasma and cerebrospinal fluid (CSF) biomarkers, including amyloid-beta 42, phosphorylated tau 181, and the inflammatory markers IL-1β, IL-18, and C-reactive protein.

Eligible participants are adults 50 to 90 years old with amyloid pathology confirmed by PET scan or CSF, a Clinical Dementia Rating-Global Score of 0.5 or 1.0, mild cognitive impairment or mild dementia, and objective memory impairment on the RBANS delayed memory index.

The case for targeting NLRP3 in Alzheimer disease

Neuroinflammation is increasingly viewed as a significant driver of AD pathogenesis rather than a downstream bystander process.3 In laboratory studies, amyloid-beta fibrils activate the NLRP3 inflammasome inside microglia, the brain's resident immune cells, triggering release of the pro-inflammatory cytokines interleukin (IL)-1β and IL-18; blocking NLRP3 fully suppresses that cytokine release.4-6

That inflammatory signal, in turn, has been shown to promote tau phosphorylation and subsequent neuronal dysfunction, giving the NLRP3 pathway a proposed mechanistic role linking amyloid and tau, the disease's two defining pathologies.7 Autopsy studies have separately found NLRP3 upregulated in the brain tissue of people who had Alzheimer disease.8

That biomarker case gained clinical support earlier in 2026. In a reverse-translational analysis of CSF samples banked from more than 500 participants in Roche's completed GRADUATE phase 3 program, presented at the Alzheimer's Association International Conference, participants with higher baseline NLRP3-related marker levels progressed faster on measures of cognitive decline than those with lower levels.4 Gennaro Pagano, MD, PhD, of Roche and Genentech, a senior author on the TARBELA-AD poster, said the finding showed “that the pathway is activated in the brain,” and described NLRP3 inhibition as offering “a powerful synergistic combination with current amyloid-lowering drugs.”4

Those biomarker findings followed RG6434's own first-in-human program, which began dosing in September 2024. The ongoing phase 1 study is testing single and multiple ascending oral doses of RG6434 in healthy volunteers, including a food-effect cohort, before extending into about 4 weeks of dosing in people with early Parkinson disease, a separate condition in which NLRP3-driven neuroinflammation has also been implicated. The trial's focus throughout has been safety and tolerability, and its results, informing the dose selection now being tested in TARBELA-AD, have not yet been publicly reported.9

If TARBELA-AD succeeds, RG6434 would join a broader Roche AD pipeline that already includes the anti-amyloid antibody trontinemab and the investigational agent nivegacetor, each aimed at a different point in the disease process. Roche has framed the strategy as pairing amyloid clearance with complementary mechanisms, rather than relying on amyloid removal alone, as the company works to decouple amyloid accumulation from the neurodegenerative cascade that follows it.

For more coverage of CTAD 2026, click here.

REFERENCES
1. Rutten-Jacobs L, Machado V, Edison P, et al. Rationale and design of TARBELA-AD: a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease. Presented at: 2026 Clinical Trials on Alzheimer's Disease Conference; November 16-19, 2026; Boston, MA. Poster P016.
2. Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer's disease portfolio at CTAD 2026. News release. Roche. Published November 10, 2026. Accessed November 16, 2026. https://www.roche.com/media/releases/med-cor-2026-11-10
3. Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2024;25(5):321-352. doi:10.1038/s41577-024-01104-7
4. Pagano G, et al. The role of NLRP3 in Alzheimer's disease: reverse translational data from the GRADUATE phase 3 trials. Presented at: 2026 Alzheimer's Association International Conference; July 2026; London, UK.
5. Jung ES, Suh K, Han J, et al. Amyloid-β activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Syk-AMPK pathway. Aging Cell. 2022;21(5):e13623. doi:10.1111/acel.13623
6. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-678. doi:10.1038/nature11729
7. Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669-673. doi:10.1038/s41586-019-1769-z
8. Moonen S, Koper MJ, Van Schoor E, et al. Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 2023;145(2):175-195. doi:10.1007/s00401-022-02528-y
9. Roche For Patients. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson's disease. Accessed November 16, 2026. https://forpatients.roche.com/en/trials/neurodegenerative-disorder/pd/a-study-to-test-the-biological-properties-of-ro7568282-and-wheth.html

Related to this article